Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NewGenIvf GroupNIVF -9.09%14 Return-on-Tangible-Equity is -592.77% as of Dec. 2025. GuruFocus rates NIVF with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 576 Healthcare Providers & Services companies, NewGenIvf Group ranks better than 88.02% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. NewGenIvf Group's annualized net income for the quarter that ended in Dec. 2025 was $-30.68 Mil. NewGenIvf Group's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $5.18 Mil. Therefore, NewGenIvf Group's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -592.77%.
The historical rank and industry rank for NewGenIvf Group's Return-on-Tangible-Equity or its related term are showing as below:
NIVF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -39.08 Med: 6.05 Max: 474.04
Current: 284.86
During the past 5 years, NewGenIvf Group's highest Return-on-Tangible-Equity was 474.04%. The lowest was -39.08%. And the median was 6.05%.
NIVF's Return-on-Tangible-Equity is ranked better than 88.02% of 576
companies
in the Healthcare Providers & Services industry
Industry Median: 10.17
vs NIVF: 284.86
NewGenIvf Group (NAS:NIVF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
NewGenIvf Group Return-on-Tangible-Equity Related Terms
NewGenIvf Group Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for NewGenIvf Group's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIVF vs RHEP, XCRT, SYRA: Return-on-Tangible-Equity Comparison
For the Medical Care Facilities subindustry, NewGenIvf Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NewGenIvf Group Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NewGenIvf Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where NewGenIvf Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -592.77% mean?
NewGenIvf Group (NIVF) has a Return-on-Tangible-Equity of -592.77% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NewGenIvf Group and its competitors. According to the industry distribution chart, NewGenIvf Group ranks #69 out of 576 companies in the Healthcare Providers & Services industry, placing it in the top 12%.
Is NewGenIvf Group's Return-on-Tangible-Equity too high?
NewGenIvf Group's current Return-on-Tangible-Equity is -592.77%. Based on the distribution chart, NewGenIvf Group ranks #69 out of 576 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, NewGenIvf Group has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does NewGenIvf Group's Return-on-Tangible-Equity compare to RHEP and XCRT?
According to the Healthcare Providers & Services industry distribution chart, NewGenIvf Group ranks #69 out of 576 companies for Return-on-Tangible-Equity. This places NewGenIvf Group in the top 12% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 10.17. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.17, based on 576 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NewGenIvf Group and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NewGenIvf Group's current Return-on-Tangible-Equity is -592.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NewGenIvf Group stock overvalued right now?
NewGenIvf Group (NIVF) has a current Return-on-Tangible-Equity of -592.77%. The current Return-on-Tangible-Equity is -592.77%. NewGenIvf Group's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For NewGenIvf Group (NIVF), the current Return-on-Tangible-Equity is -592.77% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NewGenIvf Group Ltd is a tech-forward, diversified, multi-jurisdictional entity capitalizing on emerging opportunities across real estate development, digital asset innovation, and reproductive health solutions. The company offers two services, namely: in vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and fertility referral services, like surrogacy and ancillary caring services. It derives maximum revenue from in vitro fertilization (IVF) treatment service. Its Geographical presence is in China / HK SAR, Thailand, Cambodia, U.S and Kyrgyzstan. The company derives maximum revenue from Kyrgyzstan.
14GF Score
Get the complete analysis for NIVF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NIVF has been successfully added to your 
